Key Notes
- Remedy’s $62 million Series B will support planned pivotal trials and prototype deployments of its N1 endovascular robot.
- The investigational system combines robotic instrument control with imaging and remote-operation tools, while commercial sale remains unavailable.
- The funding supports progress toward potential FDA approval and further autonomous capabilities rather than an already authorized clinical rollout.
Remedy Robotics has raised $62 million in Series B financing to advance its N1 endovascular robot toward pivotal clinical trials and potential FDA approval. DCVC led the round, which the company detailed in a November 16 funding announcement.
The San Francisco company is developing a system intended to let physicians control instruments inside blood vessels, including remotely. N1 remains investigational: its safety and effectiveness for clinical use have not been established, and it is not available for commercial sale.
New Capital Supports Trials and Prototype Deployment
Participants include UC Investments, Skip Capital and Hostplus, alongside returning investors Build Collective, Blackbird, Divergent Capital and KdT Ventures. Remedy plans a pivotal trial with the University of California and prototype placements through its clinical partnerships, including SVIN Mission Thrombectomy and the Australian Stroke Alliance.
Those plans represent the next development stage. They do not mean that the trial has already demonstrated effectiveness or that regulators have authorized routine use. The company’s release does not give a date for FDA approval.
N1 Combines Robotic Tools With Patient-Specific Imaging
Remedy’s technology overview describes AI-assisted instrument control, automated image segmentation and preoperative simulation. Real-time 3D-2D registration is designed to connect a three-dimensional view of anatomy with images used during a procedure, helping an operator understand the position of tools.
The platform is being designed around a complete endovascular workflow, with support for off-the-shelf devices and the company’s steerable catheters. Its remote-operation package includes connectivity management, audio and video. That integration addresses the practical challenge of placing the specialist and patient in different locations while maintaining a usable operating interface.
Remedy’s clinical timeline identifies first-in-human work in Toronto in 2024 and remotely controlled procedures in 2025. Those research milestones provide development history; they are distinct from clearance for general clinical deployment.
Remote Control and Autonomy Remain Different Milestones
The company describes supervised autonomy as a development direction. A remotely operated robot follows a physician’s control from another location, whereas autonomous functions execute parts of the work through software. Evidence for one mode should not be treated as validation of the other.
The release names further autonomous capabilities among the engineering goals funded by the round. For N1, the decisive next evidence will come from its planned clinical evaluation and the regulatory process, rather than the financing amount alone.
Our reporting on medical robotics follows other systems moving toward hospital use. Akara’s hospital platform addresses a separate layer of healthcare automation: coordinating rooms, staff and equipment around clinical work.
Disclaimer: RobotsBeat is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, Robotics, technology, software, and digital innovation sectors. These relationships do not influence RobotsBeat's editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.